Statute Details
- Title: National Registry of Diseases (Specified Entity for Chronic Kidney Failure) Notification 2011
- Act Code: NRDA2007-S100-2011
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: National Registry of Diseases Act (Cap. 201B)
- Enacting Formula (Power Source): Section 24(2) of the National Registry of Diseases Act
- Commencement: 1 March 2011
- Key Provisions in the Extract: Section 1 (Citation and commencement); Section 2 (Specified entity for chronic kidney failure)
- Legislative Instrument Number: S 100/2011 (SL 100/2011)
- Maker / Signature: Permanent Secretary, Ministry of Health (Yong Ying-I), made on 26 January 2011
- Specified Entity Identified: National Registry of Diseases Office of the Health Promotion Board
What Is This Legislation About?
The National Registry of Diseases (Specified Entity for Chronic Kidney Failure) Notification 2011 is a short but important administrative instrument. In plain terms, it designates a particular organisation as the “specified entity” responsible for collecting information relating to chronic kidney failure under Singapore’s National Registry of Diseases framework.
Singapore’s National Registry of Diseases Act establishes a legal basis for collecting, using, and managing disease-related information for public health purposes. However, the Act does not itself name every body that may be involved in disease-specific data collection. Instead, it empowers the Minister to issue notifications identifying the relevant “specified entities” for particular diseases or categories of information.
This Notification focuses specifically on chronic kidney failure. It clarifies that the National Registry of Diseases Office (NRO) housed within the Health Promotion Board (HPB) is the body designated to collect information relating to chronic kidney failure for the purposes of section 24 of the National Registry of Diseases Act.
What Are the Key Provisions?
Section 1: Citation and commencement provides the formal identity and effective date of the Notification. It states that the instrument may be cited as the “National Registry of Diseases (Specified Entity for Chronic Kidney Failure) Notification 2011” and that it comes into operation on 1 March 2011. For practitioners, this matters because it determines when the designation becomes legally effective and when any related reporting or data-collection obligations (arising under the parent Act) can be relied upon as being in force.
Section 2: Specified entity for chronic kidney failure is the substantive provision. It declares that the National Registry of Diseases Office of the Health Promotion Board is the specified entity for collecting information relating to chronic kidney failure for the purposes of section 24 of the National Registry of Diseases Act.
Although the extract does not reproduce section 24 of the Act, the legal effect of section 2 is clear: it links the disease-specific data collection function to a named institutional actor. In practice, this designation is typically relevant to how information is gathered, who is authorised to receive or handle it, and how the statutory scheme is implemented operationally. By naming the HPB’s National Registry of Diseases Office, the Notification ensures that there is no ambiguity about which body is intended to carry out the registry’s chronic kidney failure information collection mandate.
Enacting formula and administrative context also provide useful legal guidance. The Notification is made “in exercise of the powers conferred by section 24(2) of the National Registry of Diseases Act.” This indicates that the Minister’s authority to designate specified entities is statutory and that the Notification is an exercise of delegated legislative power. For lawyers, this supports the validity of the instrument and helps interpret its scope: it is not merely a policy statement, but a legally operative designation grounded in the parent Act.
How Is This Legislation Structured?
This Notification is structured in a conventional, minimal format typical of subsidiary instruments that perform a narrow legal function. It contains:
(1) Enacting formula — sets out the legal power under which the Notification is made (section 24(2) of the National Registry of Diseases Act).
(2) Section 1 (Citation and commencement) — provides the name and commencement date.
(3) Section 2 (Specified entity for chronic kidney failure) — identifies the specified entity (the National Registry of Diseases Office of HPB) for the collection of information relating to chronic kidney failure under section 24 of the Act.
There are no additional parts or schedules in the extract because the instrument’s purpose is limited to the designation of an entity. The simplicity of the structure is itself legally significant: the Notification does not attempt to create detailed operational rules; instead, it performs a “gatekeeping” role within the broader statutory framework.
Who Does This Legislation Apply To?
The Notification primarily applies to the specified entity it designates—namely, the National Registry of Diseases Office of the Health Promotion Board. In legal terms, the designation is relevant to the operation of section 24 of the National Registry of Diseases Act, which governs the collection of information relating to chronic kidney failure.
While the Notification does not expressly list reporting institutions (such as hospitals, clinics, laboratories, or clinicians), those obligations—if any—would typically arise from the parent Act and any associated regulations or notifications. The practical effect is that healthcare providers and other stakeholders who interact with the registry may need to understand that the HPB’s National Registry of Diseases Office is the statutory recipient/collector for chronic kidney failure information under the Act’s section 24 framework.
Why Is This Legislation Important?
Even though this Notification is brief, it is important because it determines who is legally authorised (or designated) to collect disease-related information for a specific condition. In a data-driven public health system, the identity of the collecting entity affects governance, accountability, and compliance. By naming the National Registry of Diseases Office within HPB, the Notification ties chronic kidney failure data collection to a particular institutional structure.
From a legal practitioner’s perspective, the Notification supports several practical tasks:
- Compliance mapping: advising healthcare organisations on where and to whom information should be provided under the National Registry of Diseases Act for chronic kidney failure.
- Regulatory certainty: reducing uncertainty about whether data collection is being carried out by the correct statutory body.
- Governance and accountability: clarifying the responsible registry office, which is relevant when assessing internal controls, data handling practices, and audit trails.
It is also significant because it demonstrates how Singapore’s registry regime operates through a combination of a principal Act and targeted notifications. The Act provides the overarching legal architecture; notifications then specify the operational actors for particular disease categories. This approach allows the system to evolve—such as by designating different entities for different diseases—without amending the Act each time.
Finally, the commencement date (1 March 2011) is relevant for any disputes or compliance assessments that depend on whether a designation was in force at a particular time. For example, if an organisation’s data submission practices began before or after the commencement date, the Notification may be used to determine the legal baseline for the registry’s chronic kidney failure information collection arrangements.
Related Legislation
- National Registry of Diseases Act (Cap. 201B) — the authorising Act, including section 24 (not reproduced in the extract), under which the Minister may designate specified entities.
- Health Promotion Board Act (Cap. 122B) — establishes the Health Promotion Board, within which the National Registry of Diseases Office is located.
- Timeline / Legislation history resources — useful for confirming the current version and any amendments (the instrument indicates “current version as at 27 Mar 2026” and references SL 100/2011).
Source Documents
This article provides an overview of the National Registry of Diseases (Specified Entity for Chronic Kidney Failure) Notification 2011 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.